- Join the Innovation Journey
- Our Platforms
Platform 10: Antibody Humanisation
Antibody humanisation enables promising antibody candidates from non-human species to be modified so that they are applicable to humans.
LifeArc, a leading self-funded medical research charity, has joined iiCON as a consortium partner to make its expertise in the field of antibody humanisation available to research groups and organisations developing new antibodies for infectious diseases.
LifeArc’s expertise and track record of success in this field has helped transform the way many conditions are treated. With more than 90 antibodies humanised for 51 companies over the past 30 years, it has contributed to five marketed therapeutics. These results have been achieved by working with research teams and organisations to humanise and optimise the antibodies they have developed for clinical use – moving them closer towards patient impact.
LifeArc’s highly collaborative model supports innovation by de-risking innovation. If a project is selected for progression through its programme, LifeArc will take on the development risks and work closely with the team to progress the opportunity.
With huge untapped opportunity for antibodies in infectious diseases, this platform provides streamlined access to LifeArc’s leading humanisation capability coupled with iiCON’s highly-specialist infectious disease expertise that supports every stage of the product development journey from discovery to patient impact.
Find out more about LifeArc’s approach and leading antibody engineering capability here
For more information or to learn how your business can engage with this platform.
Platform Lead
Dr Preeti Bakrania,
Scientific Director, Biologics Discovery and Development, LifeArc
Preeti Bakrania, leads the Biologics Discovery and Development team in LifeArc’s Therapeutic Translation Platform group within Translational Sciences. She oversees a team of 25 scientists based at our sites in Stevenage and the Francis Crick Institute who are dedicated to the successful delivery of high-quality biological therapeutics to support LifeArc’s Portfolio. She obtained her PhD in Biochemistry at the National Institute for Medical Research and has more than 20 years research experience working in a number of disease areas including neuroscience, oncology and ophthalmology with postdoctoral roles held within UCL, University of Cambridge and University of Oxford. She joined LifeArc 15 years ago and is an experienced project and portfolio manager where she managed LifeArc’s world-leading antibody humanisation portfolio, which has been involved in the development of five commercialized drugs, including Keytruda® and Leqembi® and also led LifeArc’s portfolio to generate fully human antibodies using the Intelliselect® Transgenic Platforms against a number of target classes across a wide range of disease areas for pre-clinical development. Preeti is a passionate scientist who thrives on the successful delivery of drug discovery programs to the clinic for the benefit of patient healthcare and has a track record of success with a number of publications, named inventor on four patents and has been a Board Observer for DJS antibodies which was recently acquired by Abbvie.
Read more
